Based on results from the phase 3 CAPItello-281 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that capivasertib plus abiraterone and ADT demonstrates a favorable benefit-risk profile in PTEN-deficient metastatic...
Based on results from the phase 3 CAPItello-281 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that capivasertib plus abiraterone and ADT demonstrates a favorable benefit-risk profile in PTEN-deficient metastatic...
Based on results from the phase 3 VERITAC-2 trial, the FDA has approved vepdegestrant for patients with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.
Based on results from the phase 3 VERITAC-2 trial, the FDA has approved vepdegestrant for patients with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.
Based on results from the phase 3 RINGSIDE trial, a New Drug Application for varegacestat has been submitted to the FDA for the treatment of adult patients with desmoid tumors.
Based on results from the phase 3 RINGSIDE trial, a New Drug Application for varegacestat has been submitted to the FDA for the treatment of adult patients with desmoid tumors.
Results from a post hoc analysis of the phase 3 DeFi trial demonstrate that nirogacestat provides consistent clinical benefit across prognostic subgroups of patients with desmoid tumors.
Results from a post hoc analysis of the phase 3 DeFi trial demonstrate that nirogacestat provides consistent clinical benefit across prognostic subgroups of patients with desmoid tumors.
Final results from the phase 3 BRIGHT-2 trial demonstrated that bireociclib plus fulvestrant significantly improves PFS compared with fulvestrant alone in previously treated HR-positive, HER2-negative advanced breast cancer.
Final results from the phase 3 BRIGHT-2 trial demonstrated that bireociclib plus fulvestrant significantly improves PFS compared with fulvestrant alone in previously treated HR-positive, HER2-negative advanced breast cancer.
Results from the phase 3 RECITE trial demonstrated that romiplostim significantly reduced the need for chemotherapy dose modifications in patients with chemotherapy-induced thrombocytopenia.
Results from the phase 3 RECITE trial demonstrated that romiplostim significantly reduced the need for chemotherapy dose modifications in patients with chemotherapy-induced thrombocytopenia.
Results from the phase 3 TACO trial demonstrate that tri-weekly cisplatin provides similar survival with improved safety and quality of life vs weekly dosing in patients with locally advanced cervical cancer.
Results from the phase 3 TACO trial demonstrate that tri-weekly cisplatin provides similar survival with improved safety and quality of life vs weekly dosing in patients with locally advanced cervical cancer.
Based on data from the phase 1/2 CARDINAL study, the FDA has granted breakthrough therapy designation to TERN-701 for previously treated Ph-positive chronic myeloid leukemia.
Based on data from the phase 1/2 CARDINAL study, the FDA has granted breakthrough therapy designation to TERN-701 for previously treated Ph-positive chronic myeloid leukemia.
Results from a phase 1 study demonstrate that HSK42360 shows promising clinical activity with favorable safety in patients with BRAF V600-mutant gliomas.
Results from a phase 1 study demonstrate that HSK42360 shows promising clinical activity with favorable safety in patients with BRAF V600-mutant gliomas.
Based on results from the phase 3 CAPItello-281 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that capivasertib plus abiraterone and ADT demonstrates a favorable benefit-risk profile in PTEN-deficient metastatic...
Based on results from the phase 3 CAPItello-281 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that capivasertib plus abiraterone and ADT demonstrates a favorable benefit-risk profile in PTEN-deficient metastatic...
Based on results from the phase 3 VERITAC-2 trial, the FDA has approved vepdegestrant for patients with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.
Based on results from the phase 3 VERITAC-2 trial, the FDA has approved vepdegestrant for patients with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.
Based on results from the phase 3 RINGSIDE trial, a New Drug Application for varegacestat has been submitted to the FDA for the treatment of adult patients with desmoid tumors.
Based on results from the phase 3 RINGSIDE trial, a New Drug Application for varegacestat has been submitted to the FDA for the treatment of adult patients with desmoid tumors.
Results from a post hoc analysis of the phase 3 DeFi trial demonstrate that nirogacestat provides consistent clinical benefit across prognostic subgroups of patients with desmoid tumors.
Results from a post hoc analysis of the phase 3 DeFi trial demonstrate that nirogacestat provides consistent clinical benefit across prognostic subgroups of patients with desmoid tumors.
Final results from the phase 3 BRIGHT-2 trial demonstrated that bireociclib plus fulvestrant significantly improves PFS compared with fulvestrant alone in previously treated HR-positive, HER2-negative advanced breast cancer.
Final results from the phase 3 BRIGHT-2 trial demonstrated that bireociclib plus fulvestrant significantly improves PFS compared with fulvestrant alone in previously treated HR-positive, HER2-negative advanced breast cancer.
Results from the phase 3 RECITE trial demonstrated that romiplostim significantly reduced the need for chemotherapy dose modifications in patients with chemotherapy-induced thrombocytopenia.
Results from the phase 3 RECITE trial demonstrated that romiplostim significantly reduced the need for chemotherapy dose modifications in patients with chemotherapy-induced thrombocytopenia.
Results from the phase 3 TACO trial demonstrate that tri-weekly cisplatin provides similar survival with improved safety and quality of life vs weekly dosing in patients with locally advanced cervical cancer.
Results from the phase 3 TACO trial demonstrate that tri-weekly cisplatin provides similar survival with improved safety and quality of life vs weekly dosing in patients with locally advanced cervical cancer.
Based on data from the phase 1/2 CARDINAL study, the FDA has granted breakthrough therapy designation to TERN-701 for previously treated Ph-positive chronic myeloid leukemia.
Based on data from the phase 1/2 CARDINAL study, the FDA has granted breakthrough therapy designation to TERN-701 for previously treated Ph-positive chronic myeloid leukemia.
Results from a phase 1 study demonstrate that HSK42360 shows promising clinical activity with favorable safety in patients with BRAF V600-mutant gliomas.
Results from a phase 1 study demonstrate that HSK42360 shows promising clinical activity with favorable safety in patients with BRAF V600-mutant gliomas.
